Real-World Treatment Patterns and Clinical Outcomes of Baricitinib in Rheumatoid Arthritis Patients in Spain : Results of a Multicenter, Observational Study in Routine Clinical Practice (The ORBIT-RA Study)
Hernández-Cruz, Blanca (Hospital Universitario Virgen Macarena (Sevilla, Andalusia))
Rosas, José (Hospital Marina Baixa (La Vila Joiosa, Alacant))
Diaz-Torne, Cesar (Institut d'Investigació Biomèdica Sant Pau)
Belzunegui, Joaquín (Hospital Universitario de Donostia (Sant Sebastià, País Basc))
García-Vicuña, Rosario (Hospital Universitario de La Princesa. Servicio de Reumatología. IIS-IP)
Inciarte-Mundo, José (Hospital Clínic i Provincial de Barcelona)
Pons, Ana (Hospital Marina Baixa (La Vila Joiosa, Alacant))
Millán, Ana M. (Institut d'Investigació Biomèdica Sant Pau)
Jeria-Navarro, Sicylle (Institut d'Investigació Biomèdica Sant Pau)
Valero, Jesús A. (Hospital Universitario de Donostia (Sant Sebastià, País Basc))
García-Castañeda, Noelia (Hospital Universitario de La Princesa. Servicio de Reumatología. IIS-IP)
Valero Martínez, Cristina (Hospital Universitario de La Princesa. Servicio de Reumatología. IIS-IP)
Llorente Cubas, Irene (Hospital Universitario de La Princesa. Servicio de Reumatología. IIS-IP)
Calvo, Alberto (Hospital Universitario de La Princesa. Servicio de Reumatología. IIS-IP)
Díaz-Cerezo, Silvia (Lilly Spain. Medical Department)
Núñez, Mercedes (Lilly Spain. Medical Department)

Data:	2022
Resum:	Introduction: Baricitinib is an oral Janus kinase (JAK)1/JAK2 inhibitor approved to treat rheumatoid arthritis (RA). This study aimed to investigate patients' characteristics, prescription patterns, effectiveness, and treatment persistence in patients receiving baricitinib in real-world practice in Spain. Methods: This retrospective longitudinal cohort study conducted in five rheumatology units included adults with RA initiating baricitinib (Sep-2017-May-19) with at least a 6-month-follow-up. Demographic/clinical characteristics, prescription patterns, and changes in disease activity and pain level were collected until treatment discontinuation/end of follow-up. Treatment persistence was estimated by Kaplan-Meier methods. Results: Data from 182 patients were included (mean (SD)): 83. 5% women, 62. 2 (12. 3) years, body mass index 26. 8 (5. 1), disease duration 13. 2 (10. 8) years and Charlson Comorbidity Index score 2. 4 (2. 0). All patients had received at least one conventional synthetic disease-modifying anti-rheumatic drugs (csDMARD) before starting baricitinib and 78. 0% at least one biologic disease-modifying anti-rheumatic drugs (bDMARD). Furthermore, 90. 1% started with baricitinib 4 mg/day; 43. 4% in monotherapy. One hundred and twelve (61. 5%) of patients continued baricitinib at data collection time; mean persistence was 14. 1 (0. 5) months. Overall treatment persistence was 79. 7/64. 8/59. 1% at 6/12/18 months. Seventy (38. 5%) patients discontinued baricitinib during follow-up due to loss of efficacy (68. 6%) or adverse events (18. 6%). In those patients with available scores at the different observed cut-off points, remission or low disease activity was reported in 71. 6 and 76. 3% of patients at 6/12 months at any index: Disease Activity Score 28 joints using erythrocyte sedimentation rate (DAS28-ESR) (73. 1 and 73. 5%), Simplified Disease Activity Index (SDAI) (62. 4 and 75. 0%), and Clinical Disease Activity Index (CDAI) (66. 7 and 78. 1%). Good or moderate European League Against Rheumatism (EULAR)-response was noted in 80. 0 and 78. 2% of patients, respectively. Improvement from baseline in pain (Visual Analog Scale) was 2. 5 cm and 3. 0 cm at 6/12 months, respectively. Conclusions: This Spanish cohort of patients treated with baricitinib had a long-standing and refractory disease. Nevertheless, high persistence and improvements in disease activity and pain were found at 6 and 12 months after treatment initiation, independently of the composite disease activity measure used, reinforcing the effectiveness of baricitinib in routine clinical practice.
Nota:	Altres ajuts: Eli Lilly and Company, Indianapolis, IN, USA.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Rheumatoid arthritis ; Retrospective observational study ; Baricitinib ; Treatment patterns ; Effectiveness ; Persistence ; Spain
Publicat a:	Rheumatology and Therapy, Vol. 9 Núm. 2 (april 2022) , p. 589-608, ISSN 2198-6584

DOI: 10.1007/s40744-021-00423-8
PMID: 35041155

20 p, 1.2 MB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut de Recerca Sant Pau
Articles > Articles de recerca
Articles > Articles publicats